Surgical Robotics Company Vicarious Surgical To Merge With D8 SPAC In $1.1Bn Deal
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
You may also be interested in...
The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.
Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.
The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.